针对选择性蛋白质降解的免疫蛋白酶N-Degron产药的合成
Cody A Loy1,2, Timothy J Harris1,2, Darci J Trader1,3,4
1Department of Pharmaceutical Science, University of California, Irvine, California.
Current protocols
|December 13, 2025
概括
研究人员开发了一种由免疫蛋白酶体 (iCP) 激活的新型"化"N-降解降解剂. 这种针对性蛋白质降解方法提高了选择性和稳定性,为癌症和炎症疾病提供了更安全的治疗方法.
科学领域:
- 生物化学 生物化学
- 化学生物学 化学生物学
- 药物发现 药物发现 药物发现
背景情况:
- 使用PROTACs的向蛋白质降解受到E3酶可用性和细胞选择性的限制.
- N-degron降解剂提供了一个较小的,类似于药物的替代品,但缺乏组织特异性的激活,容易发生蛋白质分解.
研究的目的:
- 开发一种具有对活动空间控制的新型N-degron降解剂.
- 在疾病环境中,通过免疫蛋白酶体 (iCP) 选择性激活的降解剂.
主要方法:
- 设计了一个"子"N-降解降解剂,通过添加一个iCP识别四来屏蔽降解.
- 合成和表征了N-degron降解剂和一个免疫蛋白酶N-degron前药物.
- 评估细胞中的蛋白质降解,以评估选择性和效力.
主要成果:
- 中的N-降解降解剂表现出更好的稳定性和更强的降解效率.
- 在iCP表达细胞中实现了选择性激活,最大限度地降低了健康细胞中的活性.
- 该设计策略被证明可以用于控制疾病特异性蛋白质溶解环境中的N-degron活性.
结论:
- 开发了一种用于空间控制的基于N-degron的蛋白质降解的新策略.
- 免疫蛋白酶激活降解剂为治疗应用提供了更高的安全性和选择性.
- 这种方法促进了针对癌症和炎症疾病的向蛋白质降解疗法的开发.
相关概念视频
The Proteasome
10.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.0K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome Structure
1.5K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.5K
Immunoprecipitation
6.7K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.7K
Prodrugs
3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.8K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K


